The Current Ratio as of December 2025 (TTM) for Insight Molecular Diagnostics Inc. (0KCC.L) is 4.04

According to Insight Molecular Diagnostics Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 4.04. This represents a change of 62.65% compared to the average of 2.48 of the last 4 quarters.

Insight Molecular Diagnostics Inc. (0KCC.L) Historical Current Ratio (quarterly & annually)

How has 0KCC.L Current Ratio performed in the past?

The mean historical Current Ratio of Insight Molecular Diagnostics Inc. over the last ten years is 2.53. The current 4.04 Current Ratio has changed 15.82% with respect to the historical average. Over the past ten years (40 quarters), 0KCC.L's Current Ratio was at its highest in in the March 2019 quarter at 12.82. The Current Ratio was at its lowest in in the September 2024 quarter at 0.53.

Insight Molecular Diagnostics Inc. (0KCC.L) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Insight Molecular Diagnostics Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Insight Molecular Diagnostics Inc. (0KCC.L) Average Current Ratio

How has 0KCC.L Current Ratio performed in the past?

The current Current Ratio of Insight Molecular Diagnostics Inc. (0KCC.L) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Insight Molecular Diagnostics Inc. (0KCC.L) Current Ratio vs. Peers

How is 0KCC.L’s Current Ratio compared to its peers?

Insight Molecular Diagnostics Inc.’s Current Ratio is greater than Sangamo Therapeutics, Inc. (1.05), greater than Heron Therapeutics, Inc. (0.82), less than Codexis, Inc. (4.12), greater than Accuray Incorporated (1.62), less than Corbus Pharmaceuticals Holdings, Inc. (9.21), less than Abeona Therapeutics Inc. (9.74), greater than Atara Biotherapeutics, Inc. (1.70), greater than Aclaris Therapeutics, Inc. (3.88), greater than Editas Medicine, Inc. (2.77), less than Adicet Bio, Inc. (7.48),

Build a custom stock screener for Insight Molecular Diagnostics Inc. (0KCC.L) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Insight Molecular Diagnostics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Insight Molecular Diagnostics Inc. (0KCC.L) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Insight Molecular Diagnostics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.